» Articles » PMID: 25230936

Determination of Specific Antibody Responses to the Six Species of Ebola and Marburg Viruses by Multiplexed Protein Microarrays

Overview
Date 2014 Sep 19
PMID 25230936
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Infectious hemorrhagic fevers caused by the Marburg and Ebola filoviruses result in human mortality rates of up to 90%, and there are no effective vaccines or therapeutics available for clinical use. The highly infectious and lethal nature of these viruses highlights the need for reliable and sensitive diagnostic methods. We assembled a protein microarray displaying nucleoprotein (NP), virion protein 40 (VP40), and glycoprotein (GP) antigens from isolates representing the six species of filoviruses for use as a surveillance and diagnostic platform. Using the microarrays, we examined serum antibody responses of rhesus macaques vaccinated with trivalent (GP, NP, and VP40) virus-like particles (VLP) prior to infection with the Marburg virus (MARV) (i.e., Marburg marburgvirus) or the Zaire virus (ZEBOV) (i.e., Zaire ebolavirus). The microarray-based assay detected a significant increase in antigen-specific IgG resulting from immunization, while a greater level of antibody responses resulted from challenge of the vaccinated animals with ZEBOV or MARV. Further, while antibody cross-reactivities were observed among NPs and VP40s of Ebola viruses, antibody recognition of GPs was very specific. The performance of mucin-like domain fragments of GP (GP mucin) expressed in Escherichia coli was compared to that of GP ectodomains produced in eukaryotic cells. Based on results with ZEBOV and MARV proteins, antibody recognition of GP mucins that were deficient in posttranslational modifications was comparable to that of the eukaryotic cell-expressed GP ectodomains in assay performance. We conclude that the described protein microarray may translate into a sensitive assay for diagnosis and serological surveillance of infections caused by multiple species of filoviruses.

Citing Articles

Isolation of infectious Lloviu virus from Schreiber's bats in Hungary.

Kemenesi G, Toth G, Mayora-Neto M, Scott S, Temperton N, Wright E Nat Commun. 2022; 13(1):1706.

PMID: 35361761 PMC: 8971391. DOI: 10.1038/s41467-022-29298-1.


Rhesus Macaque CODEX Multiplexed Immunohistochemistry Panel for Studying Immune Responses During Ebola Infection.

Jiang S, Mukherjee N, Bennett R, Chen H, Logue J, Dighero-Kemp B Front Immunol. 2021; 12:729845.

PMID: 34938283 PMC: 8685521. DOI: 10.3389/fimmu.2021.729845.


Simultaneous Detection of Ebola Virus and Pathogens Associated With Hemorrhagic Fever by an Oligonucleotide Microarray.

Yao W, Yang Z, Lou X, Mao H, Yan H, Zhang Y Front Microbiol. 2021; 12:713372.

PMID: 34394063 PMC: 8363200. DOI: 10.3389/fmicb.2021.713372.


Development of a multiplex microsphere immunoassay for the detection of antibodies against highly pathogenic viruses in human and animal serum samples.

Surtees R, Stern D, Ahrens K, Kromarek N, Lander A, Kreher P PLoS Negl Trop Dis. 2020; 14(10):e0008699.

PMID: 33095766 PMC: 7641473. DOI: 10.1371/journal.pntd.0008699.


A Smartphone-Based Rapid Telemonitoring System for Ebola and Marburg Disease Surveillance.

Natesan M, Wu S, Chen C, Jensen S, Karlovac N, Dyas B ACS Sens. 2018; 4(1):61-68.

PMID: 30525467 PMC: 6350200. DOI: 10.1021/acssensors.8b00842.


References
1.
Yonezawa A, Cavrois M, Greene W . Studies of ebola virus glycoprotein-mediated entry and fusion by using pseudotyped human immunodeficiency virus type 1 virions: involvement of cytoskeletal proteins and enhancement by tumor necrosis factor alpha. J Virol. 2004; 79(2):918-26. PMC: 538559. DOI: 10.1128/JVI.79.2.918-926.2005. View

2.
Jasenosky L, Neumann G, Lukashevich I, Kawaoka Y . Ebola virus VP40-induced particle formation and association with the lipid bilayer. J Virol. 2001; 75(11):5205-14. PMC: 114926. DOI: 10.1128/JVI.75.11.5205-5214.2001. View

3.
Dowling W, Thompson E, Badger C, Mellquist J, Garrison A, Smith J . Influences of glycosylation on antigenicity, immunogenicity, and protective efficacy of ebola virus GP DNA vaccines. J Virol. 2006; 81(4):1821-37. PMC: 1797596. DOI: 10.1128/JVI.02098-06. View

4.
Leroy E, Rouquet P, Formenty P, Souquiere S, Kilbourne A, Froment J . Multiple Ebola virus transmission events and rapid decline of central African wildlife. Science. 2004; 303(5656):387-90. DOI: 10.1126/science.1092528. View

5.
MacNeil A, Reed Z, Rollin P . Serologic cross-reactivity of human IgM and IgG antibodies to five species of Ebola virus. PLoS Negl Trop Dis. 2011; 5(6):e1175. PMC: 3110169. DOI: 10.1371/journal.pntd.0001175. View